Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

Approval of Kerendia was based on results from the Phase III FINEARTS-HF trial, which demonstrated statistically significant ...

The US Food and Drug Administration has approved the use of finerenone (Kerendia) in heart failure (HF) patients with mildly ...

Finerenone gained FDA approval for heart failure treatment, showcasing significant benefits in reducing cardiovascular events ...

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic ...

The use of SGLT2 inhibitors has been a game-changer in the treatment of heart failure (HF). Now, another drug class has ...

Bayer announced the FDA approved finerenone, a nonsteroidal selective mineralocorticoid receptor antagonist, for the ...

Bayer AG BAYRY announced that the FDA has approved a label expansion of kidney disease drug Kerendia (finerenone). The ...

Ejection fraction measures the amount of blood pumped out of your heart’s lower chambers, or ventricles. Learn more about how it is measured.

Ejection fraction refers to how much blood the heart pumps out during a contraction. An abnormal ejection fraction can be a sign of heart failure. Some people might need treatment to improve their ...